Northeastern University

Perform hands-on research in an

NCI-funded lab

Receive one-on-one mentoring

from clinicians and researchers

Faculty Mentors
Active Grants

Our Mentors

Nathalie Y.R. Agar, MD

Neurosurgery, Brigham and Women's Hospital

Develops & validates mass spectrometry imaging methodologies to study neuro-oncology and guide the care of patients affected by brain cancer. Students will have the opportunity to image drug and metabolite transit through the blood-brain barrier in pre-clinical animal models and clinical trial patients treated with targeted therapy, with the goal of developing new brain-penetrating agents.

Kenneth C. Anderson, MD

Oncology, Brigham and Women's Hospital

Focuses on translational research in multiple myeloma. Students will have the opportunity to characterize factors in the marrow microenvironment which allow tumor cell homing, growth and resistance to apoptosis in the marrow millieu in order to identify and validate next-generation novel small molecule and immune targeted therapies.

Carla F. Kim, Ph.D.

Genetics, Boston Children's Hospital

The broad interest of the Kim Lab is to characterize the biology of stem cells in normal lung and lung cancer. Our long-term goal is to elucidate the role of stem cells in lung homeostasis as a prerequisite to the development of therapeutic strategies that can be used to prevent or attenuate lung disease.

Ross I Berbeco, PhD

Radiation Oncology, Dana-Farber Cancer Institute

Performs theoretical and experimental studies of systemically administered nanoparticles and their role in enhancing radiation therapy for cancer treatment. Students will have the opportunity to functionalize these particles with tumor-specific targeting moieties and study how this leads to localized disruption of the tumor vasculature.

William C. Hahn, MD, PhD

Chief Operating Officer, Dana-Farber Cancer Institute

Studies cooperative genetic alterations that program malignant transformation and develops experimental model systems to study specific genetic alterations. Students will use therapeutic tumor-penetrating siRNA nanocomplexes to identify, validate, and understand potential therapeutic cancer.

Mukesh Harisinghani, MD

Director, Abdominal MRI, MGH

We develop magnetic nanoparticle-based platforms for use as magnetic resonance imaging (MRI) contrast agents in cancer diagnosis. Students will have the opportunity to study nanoparticle-enhanced MRI data from clinical trials in order to improve the detection of lymph node metastases.

Tayyaba Hasan, PhD

Professor of Dermatology, MGH

Develops novel targeted therapeutic agents for the photodynamic therapy of cancer, infections, and infectious disease through site-directed photochemistry. Students will participate in the design and testing of photoactivatable nanoparticles for the treatment of ovarian, prostate, pancreatic, or head and neck cancer.

Rani E. George, MD, PhD

Professor of Pediatrics, Harvard Medical School

Our laboratory is focused on studying neuroblastoma, an embryonically derived pediatric tumor of the peripheral sympathetic nervous system. We are interested in the following general areas: 1) identifying molecular targets that can be translated into novel therapies in metastatic neuroblastoma, and 2) unraveling the genetic perturbations that occur during development of the sympathetic nervous system and underlie neuroblastoma initiation and progression.

Kimberly Stegmaier, MD

Pediatric Oncology, Dana Farber Cancer Institute

Dr. Stegmaier’s laboratory integrates chemical biology, genomic, and proteomic approaches to discover new lead compounds and protein targets for cancer therapy. She has focused her efforts on the acute leukemias and two pediatric solid tumors of childhood: Ewing sarcoma and neuroblastoma.

Judy Lieberman, MD, PhD

Cellular and Molecular Medicine, Boston Children’s Hospital

Studies how RNA interference regulates and dysregulates cell differentiation in order to develop new drugs to treat or prevent cancer. Students will characterize anti-cancer therapeutics comprised of membrane-anchored lipoproteins that are incorporated into siRNA-loaded lipid nanoparticles.

Umar Mahmood, MD, PhD

Radiology, MGH

Develops molecular imaging tools for cancer treatment and treatment monitoring. Students will have the opportunity to create and validate new imaging probes, develop cell and animal models with clinically relevant pathologies, and aid in the clinical translation of successful technologies.

G. Mike Makrigiorgos, PhD

Radiation Oncology, Dana-Farber Cancer Institute

Applies nanoparticle-based approaches for DNA molecular diagnostics, PCR-based detection of DNA alterations, as well as the enrichment and identification of cancer biomarkers from blood-circulating DNA/RNA. We also combine site-specific image-guided irradiation with nanoparticle based approaches for enhancing detection of circulating biomarkers via ‘liquid biopsy’.

Myles Brown, MD

Director, Center for Functional Cancer Epigenetics Dana-Farber Cancer Institute

Focuses on elucidating the epigenetic factors underlying the action of steroid hormones. This work has important implications both for normal physiology and for the treatment of hormone dependent malignancies including breast and prostate cancer. He is recognized for three seminal discoveries. His lab opened the steroid receptor coregulator field, illuminated the dynamic nature of receptor and coregulator interaction with the genome and elucidated the importance of epigenetically determined distant cis-regulatory steroid receptor binding sites. His contributions have uniquely reformulated the understanding of steroid hormone action in normal physiology and in hormone-dependent cancer.

Kathleen H. Burns MD, PhD

Pathology, Dana-Farber Cancer Institute

The majority of our genome is highly repetitive sequence derived from the activities of self-propagating retrotransposons. My research focuses on roles these mobile genetic elements play in human disease. Despite their enormous impact on genome composition over evolutionary time and across virtually all eukaryotic taxa, transposons are often presumed to be inert, non-functional ‘junk DNA’, and I am one of few physician-scientists bridging this area of fundamental biology with biomedical research.

Anna Krichevsky, PhD

Neurology/Neurobiology, Brigham and Women's Hospital

The work in the laboratory focuses on small regulatory RNA molecules, microRNAs, their role in brain tumors, and potential as novel therapeutic targets and biomarkers. We are also interested in the RNA-mediated intracellular communication between brain tumors and normal cells of their microenvironment. Our overall goal is to develop basic RNA research toward a cure for glioblastoma (GBM) and other brain tumors.

Kornelia Polyak, MD, PhD

Professor of Medicine, Dana-Farber Cancer Institute

The three main areas of our interests are: (1) how to accurately predict breast cancer risk and prevent breast cancer initiation or progression from in situ to invasive disease, (2) better understand drivers of tumor evolution with special emphasis on metastatic progression and therapeutic resistance, and (3) novel therapeutic targets in breast cancer with particular focus on “bad” cancers such as triple negative breast cancer and inflammatory breast cancer. 

Co-op Locations